Primary Endpoint Successfully Met in Phase 2 Study of YG1699
Youngene Therapeutics Announced: An lmportant MedicalLeaders On Board
YG1699 Chinese Clinical Bridging Trial Was Launched inShanghai Xinhua Hospital
SGLT1/2 Inhibitor: Provide Full Cardiac Protection
Youngene Therapeutics Announced: Two lmportant MedicalLeaders On Board
YG1699 China Bridging Trial Has Been Carried Out
YG1699 Has Completed Phase l Clinical Trial With 64 HealthySubjects
YG1699 Has Completed The Single Dose Climbing And 40Subjects Have Completed The ...
The First SGLT1/2 Has been Approved Clinical Trial PermissionBv NMPA in China